Not This Time

The first human stem-cell based drug failed two late-stage clinical trials, reports the New York Times. The drug, Prochymal, from Osiris Therapeutics was made from mesenchymal stem cells from healthy young adults and was found to be no more effective than placebo in treating graft-versus-host disease. Prochymal did, however, appear to have an effect in a subset of patients. "Prochymal is having a clear effect in the liver, and that is the most underserved patient population," CEO C.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.